MASH - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease, the company announced.

Novo to buy Akero for $5.2 billion, to pocket trial liver disease drug

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,.

by HealthQuill
October 9, 2025
0 Comments

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.

Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces liver scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.